

# Watch Mattias Lundin's presentation at the BioStock Life Science Summit on October 25

**On October 25, Mattias Lundin, Lumito's CEO, presented the company and the strategy going forward at the BioStock Life Science Summit in Lund.**

The presentation can be viewed afterwards here: [Lumitos Presentation at the BioStock Life Science Summit October 25, 2023](#)

**For further information, please contact:**

---

Mattias Lundin, CEO Lumito  
E-mail: [ml@lumito.se](mailto:ml@lumito.se)  
Ph: +46 76 868 45 09

## **Lumito**

---

**Lumito** specialises in medical technology for digital pathology. Through its proprietary and patented technology, Lumito aims to provide healthcare providers with a powerful tool to meet the demands for fast and safe tissue diagnostics in personalised healthcare. The technology enables higher-contrast images without irrelevant background information, making it easier for pathologists to find cancer indications. The technology, based on Up Converting NanoParticles (UCNP), has the potential to significantly improve the diagnosis of tissue samples through higher quality analyses and shortened analysis times. The method has several potential applications, but Lumito has focused primarily on digital pathology and first on a release of SCIZYS by Lumito for use in research laboratories. The company is a spin-off of a research group at the Department of Atomic Physics and Laser Centre. [www.lumito.se/en](http://www.lumito.se/en)

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.

## **Attachments**

[Watch Mattias Lundin's presentation at the BioStock Life Science Summit on October 25](#)